Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
September 17, 2024 11:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis &...
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
September 16, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
September 04, 2024 16:15 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
August 14, 2024 16:10 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
aTyr Pharma Announces Research Study with Stanford Medicine
July 30, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
July 17, 2024 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 17, 2024 (GLOBE NEWSWIRE) -- Gliofocus is a global, registrational, randomized, controlled Phase 3 clinical trial comparing niraparib vs temozolomide in newly diagnosed...
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
July 16, 2024 09:00 ET
|
Flag Therapeutics, Inc.
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
May 23, 2024 17:09 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, May 23, 2024 (GLOBE NEWSWIRE) -- Results will be presented at American Society of Clinical Oncology (ASCO) Annual MeetingMedian overall survival was 20.3 months, nearly doubling the...
Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferation
May 08, 2024 08:45 ET
|
Brain Cancer Canada
Brain Cancer Canada grants $80k to study impact of anesthetics on brain tumor growth, led by Dr. Sujoy Banik.
Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer
May 03, 2024 11:32 ET
|
The Wistar Institute
PHILADELPHIA, PA, May 03, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often...